Mectizan

Ivermectin, the active ingredient in Mectizan, is an antiparasitic (macrocyclic lactone) presented as an oral tablet for oral use. It is employed to treat several parasitic infections, including river blindness, lymphatic filariasis, strongyloidiasis, scabies and head lice, in both endemic and non‑endemic populations.

GNH USA supplies Mectizan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mectizan is an antiparasitic medication that targets a range of helminthic and ectoparasitic diseases. - Onchocerciasis: reduces microfilarial load and helps prevent vision loss. - Lymphatic filariasis: lowers adult worm burden and decreases transmission risk. - Strongyloidiasis: eradicates intestinal larvae and prevents systemic dissemination. - Scabies: eliminates the Sarcoptes mite, relieving skin irritation. - Pediculosis: kills head lice and their eggs, controlling infestation.

Adverse reactions may occur with Mectizan use.

Common Side Effects: - Mild headache: transient and self‑limiting. - Nausea or abdominal discomfort: usually resolves without intervention. - Dizziness: may affect coordination briefly. - Skin rash: localized erythema or pruritus.

Serious or Rare Side Effects: - Severe hypotension: requires immediate medical attention. - Hepatic dysfunction: indicated by elevated transaminases. - Neurological events: such as seizures or encephalopathy, though rare.

Mectizan should be used with awareness of specific safety considerations. - Pregnancy: Category B; use only if potential benefit justifies the potential risk. - Breastfeeding: Caution advised; monitor infant for adverse reactions. - Co‑infection with Loa loa: high microfilarial loads may increase risk of severe adverse events. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. - Storage: Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Ivermectin may interact with other medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Other antiparasitics (e.g., albendazole): assess for additive toxicity. - CNS depressants (e.g., benzodiazepines): observe for enhanced sedation.